Theialife Appoints Thomas Ruggia as CEO to Lead Phase 3 Development of First-in-Class Oral Myopia Therapy
核心洞察
Theialife (搜索) has appointed Thomas Ruggia as President and CEO to advance its lead candidate ND10, a first-in-class oral therapy for pediatric myopia (搜索) progression.
ND10 (7-Methylxanthine) is an adenosine A2A receptor (搜索) antagonist supported by over 20 years of compassionate-use data from more than 1,200 children in Denmark.
Ruggia brings 25+ years of ophthalmology leadership experience from Johnson & Johnson, Alcon, and Samsara Vision (搜索), with expertise in late-stage development and commercialization.
Theialife (搜索), a late-stage clinical company developing innovative therapeutic solutions for ocular diseases, announced the appointment of Thomas Ruggia as President and Chief Executive Officer. The leadership change positions the company to advance its lead candidate ND10 into Phase 3 development for pediatric myopia (搜索) progression, addressing what the company describes as one of the largest unmet needs in ophthalmology.
Ruggia brings more than 25 years of leadership experience across ophthalmology, pharmaceutical, medical devices and consumer healthcare sectors. He joins Theialife (搜索) from Samsara Vision (搜索), where he served as CEO since 2020, leading the development and global commercialization of the Smaller Incision, New Generation Implantable Miniature Telescope (SING IMT) for patients with late-stage macular degeneration (搜索).
Executive Leadership Transition
Company co-founder Sundeep Aurora will continue to oversee scientific research and development while serving as Chairman. Aurora emphasized the strategic timing of the appointment, stating, "We are approaching a critical inflection point as we prepare to initiate Phase 3 development of ND10 in myopia (搜索) and we believe that Tom's deep expertise in ophthalmology makes him ideally suited to lead the next phase of our corporate and clinical evolution."
Ruggia's extensive background includes five years at Johnson & Johnson, where he worked across both Johnson & Johnson Vision and The Janssen Pharma Co. During his tenure, he supervised two international commercial organizations of more than 500 employees across America, Europe and Asia, and led the commercial strategy for PALUCORCEL, an investigational cell therapy for age-related macular degeneration (搜索).
ND10: First-in-Class Oral Myopia Therapy
ND10 (7-Methylxanthine) represents a first-in-class adenosine A2A receptor (搜索) antagonist being developed to slow pediatric myopia (搜索) progression. The oral therapy works by enhancing dopamine activity and strengthening collagen in the posterior sclera to stabilize eye structure and reduce ocular elongation.
The drug candidate is supported by substantial real-world evidence, with data generated over more than 20 years of compassionate-use and investigator-led trials in Denmark. According to the company, ND10 has been used in more than 1,200 children, demonstrating encouraging clinical potential and a favorable safety profile.
"ND10 is meaningfully de-risked through a combination of compelling clinical data as well as two decades of real-world evidence in a compassionate use setting in Denmark with over 1,200 children treated, with highly encouraging results to date," Ruggia commented on his appointment.
Strategic Vision and Pipeline Development
Under Ruggia's leadership, Theialife (搜索) aims to leverage its differentiated oral therapy approach to address the growing burden of pediatric myopia (搜索). The company is building a pipeline of ophthalmic programs targeting multiple indications, including dry eye disease (搜索), wet age-related macular degeneration (搜索), and corneal blindness (搜索).
Ruggia's track record includes successfully securing regulatory approvals and premium reimbursement pathways worldwide, along with demonstrated expertise in scaling ophthalmology companies through financing, global launches and reimbursement execution. His previous role at Alcon spanned fifteen years across various sales and marketing positions in North America and Asia-Pacific, culminating in his position as Country Business Head of Vision Care, where he managed a $100M business unit.
The appointment signals Theialife (搜索)'s preparation for anticipated milestones as the company advances toward Phase 3 clinical trial initiation for ND10, positioning the therapy to potentially transform the standard of care for pediatric myopia (搜索) management.